Interleukin Genetics

Interleukin Genetics to reduce workforce

Wednesday, July 5, 2017

Interleukin Genetics, Inc. has announced that it will pursue strategic alternatives for the Company and will reduce the Company’s workforce by five employees (63%) as part of a plan to reduce operating costs.

“While this decision was extremely difficult, it is important to preserve capital as we assess our options,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “I and the other Board members are personally grateful to our departing employees and the exceptional team members throughout the history of the Company who have advanced the contributions that Interleukin Genetics has made to precision medicine and to the advancement of inflammation science broadly.” 

[Read More]